Obese patients with schizophrenia and schizoaffective disorder: Efficacy of injectable long-acting risperidone

被引：0

|

作者：

Permuy, RT

Turner, MS

Bouhours, P

机构：

[1] Zwolse Poort, Raalte, Netherlands

[2] Larkfield Ctr, Glasgow, Lanark, Scotland

[3] Janssen Cilag, Issy Les Moulineaux, France

来源：

SCHIZOPHRENIA RESEARCH | 2004年 / 67卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

引用

下载

收藏

页码：175 / 175

页数：1

相关论文

共 50 条

[21] AN OPEN, RANDOMIZED, CONTROLLED COMPARISON OF LONG-ACTING INJECTABLE RISPERIDONE VS. ORAL OLANZAPINE IN SCHIZOPHRENIA & SCHIZOAFFECTIVE DISORDER
Keks, Nicholas A.
SCHIZOPHRENIA RESEARCH, 2012, 136 : S5 - S5
[22] Direct switch from atypical antipsychotics to long-acting injectable risperidone in schizophrenia and schizoaffective disorders
Vauth, R
Kusters, J
Braendle, D
SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 177 - 177
[23] MIRROR IMAGE STUDIES OF RISPERIDONE LONG-ACTING INJECTION FOR CHRONIC SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER
Einarson, T. R.
Jensen, R.
Hemels, M.
VALUE IN HEALTH, 2012, 15 (07) : A334 - A334
[24] Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone
Gharabawi, Georges M.
Lasser, Robert A.
Bossie, Cynthia A.
Zhu, Young
Amador, Xavier
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2006, 21 (04) : 233 - 240
[25] Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
Louza, Mario Rodrigues
Elkis, Helio
Ruschel, Sandra
de Oliveira, Irismar Reis
Bressan, Rodrigo Affonseca
Belmonte-de-Abreu, Paulo
Grabowski, Hamilton
Appolinario, Jose Carlos
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 391 - 398
[26] Experiences in using risperidone long-acting injectable in aged patients with schizophrenia
Harrington, Kathleen
Onufryk, Josie
INTERNATIONAL JOURNAL OF MENTAL HEALTH NURSING, 2008, 17 : A12 - A13
[27] Effects of long-acting injectable risperidone on cognitive function in patients with schizophrenia
Kim, S. W.
Lee, Y. H.
Lee, J. H.
Chung, K. H.
Yoo, J. A.
Ryu, J. H.
Yoon, J. S.
Kim, J. M.
Shin, I. S.
Yang, S. J.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S518 - S518
[28] Improved cognition observed in patients with schizophrenia with risperidone long-acting injectable
Mattys, J
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S497 - S497
[29] Clinical maintenance response with risperidone long-acting injectable (rlai) in subjects with schizophrenia or schizoaffective disorder: A 52 weeks Italian study
Rossi, A.
Bernareggi, M. M.
Giustra, M. G.
EUROPEAN PSYCHIATRY, 2008, 23 : S167 - S168
[30] Young patients (18-30 years) with schizophrenia and schizoaffective disorder: Results of direct switching to long-acting injectable risperidone (Stormi trial)
Saleem, PT
Firmino, H
Parellada, E
SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 176 - 176

← 1 2 3 4 5 →